Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moving in the right direction!
Lets keep the momentum into 2018 with some big announcements!
GLTU
Looking very promising here!
I would guess based on the last PR, they will conduct another Phase 3 specifically directed at the subgroups, or maybe the FDA provided Guidance that they can continue to file for Acceptance based on the data of the subgroups alone. Regardless of the primary endpoints not being met, the subgroups performed amazingly!
Here's to looking for a golden 2018!
Best Of Luck!
IMHO
Looked like today was going to be the day we started the next leg up...time to get away from these 52W Lows!
C'mon Cytori, provide some updates
lots of volume lately...Is this thing ready to make a jump?
Too many people trying to get out at .0002
Need to set the ask a little higher and let it breath
IMHO
Flippers who bought in over the past couple days are jumping out...
But looking at the amount of shares owned over $1, it is kind of a no brainer that big boys will be buying to average down. Silly to jump out so soon. This thing is going to run back to a buck!
IMHO
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3
1Q 2018: Results due by 03/31/2018
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
Buying picking up in anticipation?
A few really nice buys are starting to come in
Thanks Misiu,
Happy Holidays to you as well as all the other great posters on this board!
May we all find what we want in the new year!
Long CYCY!
Number 8 on Break Out Board...getting views anyway...
GL
Thanks Boro,
Hopefully a partnership or a big announcement soon!
Cheers!
Thanks Doc,
Appreciate the insight. It definitely looks like something is going on behind the scenes today. Lots of buying after hours could be the beginning of a big run! Sure would be nice to get back to within NASDAQ compliance.
Best of luck!
IMHO
https://www.clinicaltrials.gov/ct2/show/NCT02483078?term=PRO-140&recrs=abdf&rank=3
Taken from the Clinical Trials.Gov website...
Shorts are covering! Flippers are done flipping! Bring on the accumulation!
Great breakdown BL!
BlueHeel,
Sometimes when there is an offering, you must be a prior shareholder in order to participate in these type of deals as well. For instance CYTORI...just did a 10M public offering, but you have to have shares in your account to participate. You were able to buy in blocks based on the 1000's of shares you were currently holding. Just have to call your broker and ask to participate in those types of public offerings.
GL!
If you are hearing acquisitions, that's more than the rest of us. I was only aware of furthering trials...as per MAXIM whom handled the last raise. If they are picking up new stuff, it needs to be PR'ed.
Need to see this go up, not down. I've invested quite a bit here with so many promising trials underway. CYTX has a lot of irons in the coals...one of them will be a success! Hopefully sooner rather than later!
IMHO
I believe it is the big institutional investors trying to average down their position prior to the next phase 3 which will be announced in the first quarter. Positive news will send this back towards the .80 to $1.00 range.
IMHO
Time for the shorts to get burned...
ImmunoCellular Therapeutics Ltd (IMUC) Sees Large Growth in Short Interest
ImmunoCellular Therapeutics logoImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,709,519 shares, a growth of 1.8% from the October 31st total of 1,679,860 shares. Based on an average trading volume of 1,114,295 shares, the short-interest ratio is currently 1.5 days. Currently, 10.8% of the shares of the stock are sold short.
Separately, Maxim Group reissued a “hold” rating on shares of ImmunoCellular Therapeutics in a report on Thursday, August 24th.
Shares of ImmunoCellular Therapeutics (IMUC) traded down $0.01 on Wednesday, reaching $0.22. 7,178,955 shares of the company’s stock traded hands, compared to its average volume of 1,200,627. ImmunoCellular Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $4.27.
ImmunoCellular Therapeutics Company Profile
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.
Groundbreaking news! This could be topic of buyout very quickly! IMO
Lots of sells so far today...are some of the warrant holders cashing in for a 10% gain?
Anyone have a clue what is going on here?
Seems strange to have a 15% drop with no news?
No public news that is...?
Could be a great rebound play?
Thanks for any info
Still recruiting on Clinicaltrials.gov
https://www.clinicaltrials.gov/ct2/results?term=PRO-140&age_v=&gndr=&type=&rslt=&phase=2&Search=Apply
Sure would be nice to know what they are doing with that $10M they just took from us?
Lots of Volume here!
Could it be a Green Christmas?
All great Points BD!
Disclosure, I am also a Long here hiding in the background.
I have been reading the board for quite a while and enjoy all the back and forth antics as well.
Pearsby if nothing else, gets us to think about the golden carrot at the end of the string.
Misiu, Salts, Bucky, Gestalt, Fred & the Bored Lawyer all provide great DD for everyone to enjoy and it is certainly appreciated!
My Opinion, for what it is worth is that the Company is trying to get all of the warrants executed to cash in. The fully diluted share count is what is considered for a Buy Out, and warrants are a part of that. If the company can make money off of them before they are bought out...then why not get the funds coming and going? Take money from those warrant holders, then sell those same shares to the BP that may buy them out. The offer of December 22nd is for a reason...what ever that reason is...TBD, but it is coming fast. My presumption is negotiations are going on right now (NDA)...the P3 data will be released, and then if positive, all BP will be interested, and the bidding war begins.
No one makes a statement like that without confidence and data to back it up. They seem pretty confident that the warrants will be executed with the pricing, and today's 8K shows that some were executed and others that were not previously discounted are now discounted. This Company Train is moving, and I will be here riding the train to the promise land with you, or to the bottom of the canyon...either way, along for the ride!
Good Luck to Everyone!
Time for big investors to start buying again to average down their positions. There was a whole lot of buying a few weeks ago when we were waiting for the results...now that they were not that great, the shorts took possession of the PPS. With the upcoming Q12018 results of the other P3 trial, I am sure the buying will pick back up. Besides the not so good results from the last P3 can be interpreted differently to the specific hearing loss group. I am sure they are working feverishly with the FDA to get the data reevaluated for the specific subgroups, or trying to get another P3 for that specific subgroup. I suspect an announcement will be right around the corner.
IMHO
While a cannabis drug discovery company waits for its “moonshot,” it develops Keurig-style coffee pods
Published: Apr 12, 2017, 7:52 am • Updated: a day ago
By Alicia Wallace, The Cannabist Staff
The long play for Las Vegas-based GB Sciences involves developing and patenting a slew of pharmaceutical-grade cannabinoid therapies.
The short play starts with cannabis-infused coffee in a Keurig-compatible pod.
GB Sciences Inc., formerly operating as GrowBlox Sciences, inked a deal with Kush Cups to produce and distribute a line of cannabis-infused coffees and teas in single-use pods for Keurig-style coffee machines, company officials announced this week.
Financial terms were not disclosed for the agreement, which covers the production, distribution and sale of Kush Cups’ hot coffee, cold brew and teas within Nevada.
With the new partnership, the companies join a growing line of cannabis firms that have produced marijuana-infused coffee pods.
“I feel beyond strong. Words can’t explain,” Rick Chavez, founder of Kush Cups Nevada LLC, told The Cannabist. “A lot of people have this perception that a lot of categories in this industry are full. … There’s just endless possibilities.”
For Kush Cups, the company aimed to differentiate itself from the crowd by launching strain-specific coffee and tea products made via a cold-water hash-infused process, Chavez said. Until now, the products have been sold mostly in California with some presence in Arizona and Colorado, but the sourcing, testing and distribution aspects have been somewhat disjointed.
“This is allowing us to enter the Nevada market and perform a seamless operation from production all the way to (distribution),” he said.
And for GB Sciences, it’s the first deal of its kind for the firm and, as such, represents a key step toward building the company’s brand and meeting long-term goals, CEO John Poss said in an interview with The Cannabist.
“We’re not expecting this Kush deal to make or break us,” he said. “It’s the first in a series of deals we expect to announce where we will be signing up brands for Nevada and other states.”
While GB Sciences will make some plays in the infused products arena — Poss recently got a call from an energy drinks maker, for example — the heart of the operation remains entrenched in the science.
GB Sciences’ focus there includes cultivation, production, delivery technologies and drug discovery.
Earlier this year, the company opened a 28,000-square-foot cultivation facility in Vegas that has the capacity to grow 4,000 plants and generate upward of $20 million in revenue annually, officials announced in January. GB Sciences plans to employ clean-room technology and incorporate practices to eventually qualify for the Food & Drug Administration’s Good Manufacturing Standards, Poss said.
The company has a couple of patent application in motion for a multiple-cannabinoid approach to target specific diseases, Poss said. GB Sciences is working with a contract research organization to identify the best path for those discoveries — be it a route direct to dispensary, dietary supplement or FDA-approved drug.
“We’re building a good, solid, cash-flow company with an embedded moonshot,” he said.
Poss said GB Sciences is operating like a pre-revenue startup and should start generating revenue in its current fiscal year, which began on April 1. The latest quarterly filing for GB Sciences (OTCQB: GBLX) shows the company had an operating loss of $6.6 million for the nine-month period that ended on Dec. 31, and a net loss of $7.3 million, according to U.S. Securities and Exchange Commission documents.
“We’ll grow and sell high-quality cannabis-infused (products),” he said. “All the while, we’re trying to launch a ship to Mars with one of these FDA-approved drugs.”
GB Sciences Partners with Kush Cups to Produce Cannabis-Infused Keurig-Compatible K-Cups, Brewed Coffee and Infused Tea
LAS VEGAS, April 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and Arizona-based Kush Cups signed an agreement Tuesday to produce cannabis-infused products in the state of Nevada.
GB Sciences utilizes advanced propagation technology, raw tissue, and grows in medical-grade clean rooms, so that the venture is ensured of consistent cannabis ingredients for its infused products.
"We've paired with a strong partner here. We are confident GB Sciences will distribute the Kush Cups successfully in Nevada," said Rick Chavez, founder of Kush Cups Nevada LLC.
GB Sciences will grow the cannabis in their state-of-the-art Cultivation Labs facility in Las Vegas and distribute cannabis-infused Keurig-compatible K-Cups, hot and cold brew coffees as well as infused teas.
"We're excited to join forces with Kush Cups. They have an excellent line of products and are the leaders in their space in Nevada," said GB Sciences CEO John Poss. "Our partnership is positioned for maximum impact in the Nevada market. It is the first major step in our strategy to be a trusted ingredient in leading brands of infused products and therapies."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: www.GBSciences.com.
About Kush Cups
With over 15 years of marijuana edible manufacturing experience, the team at Kush Cups sources the highest quality strains in the manufacturing of the best medicinal coffee and teas in the industry, and is the only manufacturer producing products compatible for Keurig machines.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com
Investors: John Poss, j.poss@gbsciences.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gb-sciences-partners-with-kush-cups-to-produce-cannabis-infused-keurig-compatible-k-cups-brewed-coffee-and-infused-tea-300437177.html
GB Sciences, INC.....NAME CHANGE
I was thinking the same thing Tek, once the Rexista technology is FDA approved, I am thinking other drugs will follow suit. whether that is IPCI formulation on their own, or licensing out the technology, it could be earth shattering where all the abuse deterrent technology can be employed.
Best of Luck!
Cut from an old interview...
Are there any other products you’d like to talk about that are in the midst of development?
Dr. Odidi: Yes, in addition to the 15 products that are currently in our pipeline, we are constantly looking for opportunities where we can exploit the Hypermatrix technology and our internal expertise. It is well known that there are many patent expirations threatening major products for most large pharmaceutical companies. This is a huge opportunity for us. As such, we are actively seeking to license our proprietary drug delivery platforms to owners of patented, branded multiple-dose-per-day products. The natural life cycle of those products can potentially be extended far beyond the expiry of the underlying patents, when ordinarily generic introductions might be expected to cause substantial sales erosion. The development of a proprietary controlled-release formulation for sale under the banner of the original, established brand is a sound brand management strategy which pharmaceutical companies often consider long before the expiry of the patents. We will also continue to seek opportunities for developing difficult-to-formulate generics and applying our technology to the development of new products where the benefits of the application of our technology would provide a clear competitive advantage, similar to what we are doing with our Rexista product.
http://files.shareholder.com/downloads/ABEA-43EQSZ/3895216196x0x360649/37C6C105-9C30-4E8F-8026-DD017F961618/IntelliPharmaCeutics.pdf
IntelliPharmaCeutics CEO Dr. Issa Odidi on preventing overdose death from Oxycodone, Fentanyl
February 23, 2017 Transcript:
James West: Dr. Odidi, thank you for joining us today.
Dr. Isa Odidi: Thank you very much for having me, and thanks to all the listeners out there, all those who are looking at this online or through whatever medium. Thanks.
James West: Let’s start with an overview of what is the value proposition for investors in Intellipharmaceutics?
Dr. Isa Odidi: Basically, the value proposition is that we are a company that is growing and we are at an inflection point at this current time; and (we)filed several ANDAs in the United States of which three have been approved, and we’re set to put one of them into the market soon, sometime around May. And I think the big thing happening now is the NDA that we filed for an abuse deterrent oxycodone medication for pain in the United States as a 505(b)(2) filing. I think we are currently awaiting FDA acceptance letter for that particular filing, and that is certainly a big milestone for this company. And of course, we have several other products in the pipeline.
James West: Are these products for pain management, are they opioid based?
Dr. Isa Odidi: Yes, they are opioid-based products and various combination products; particularly we’re looking at exploring the technology which are approved on the two new patents that we recently received. These are technologies to prevent overdose. I feel strongly that that will be a game-changer if we are able to prove that this technology actually works in real practice.
James West: I see. So this would have direct implications for the fentanyl overdose epidemic, I guess?
Dr. Isa Odidi: Most specifically for overdose from taking solid oral dosage opiates, for example, oxycodone, hydromorphone, hydrocodone, morphine, and the like, particularly in situations where you have a combination product of oxycodone and paracetamol, which is basically what’s in Tylenol. Typically, I don’t want to mention trade names, I don’t want to label other companies’ products, but typically there are products on the market that contain oxycodone, say, a low dose of 5 milligrams for example, and also contain paracetamol. People, in trying to get access to the oxycodone, only 5 milligrams, they tend to want to take many of those tablets at one time. The problem is that when they take multiple tablets of that product combination, they are basically taking too much of paracetamol, and this has very serious untoward effects on liver, and they really get hurt.
In such situations, if our technology, the PODRAS,what we call Paradoxical Overdose Resistance Activating System, it is incorporated in such a formulation or such a tablet combination, they won’t be able to feel that impact, because the large dose of paracetamol will not be released at all.
James West: Interesting. So what is the target market size, then, for this kind of a product?
Dr. Isa Odidi: I know people have looked at it including ourselves and with this sort of technology, basically, I wouldn’t even call it a product because it’s applicable to any solid oral dose form; it’s quite a huge market we’re looking at here, not just opiates, but in any situation where overdose becomes an issue, this technology could be used. We are talking in the billions, if the product works.
James West: Sure. Okay, and so for Intellipharmaceutics, how much money have you put into the company to get it to this point of evolution? How much has been invested in the company altogether?
Dr. Isa Odidi: That’s a very good question. I’ve not been doing any back-of-the-envelope math for this, but several millions have gone in. It could be close to $100 million gone into the company, but that is the way it is right now, and that’s little money compared to most other companies. And I think that’s one of the things we take pride in. We’re a very nimble operation, very effective with limited resources.
James West: Great. How did you start this company, and what’s your background?
Dr. Isa Odidi: My background is in pharmacy. I read pharmacy as a first degree, then I did a Masters in pharmaceutical technology at Kent College, University of London. And then I did a PhD in Pharmaceutics at School of Pharmacy, University of London. I have an MBA from Rotman School of Management, University of Toronto, and I’ve been to Harvard to do some other management programs as well.
I started this company after leaving Biovail together with my wife, Dr. Amina Odidi, who herself has similar qualifications. We came to Canada in 1995 to come and help Biovail, which was owned by Eugene Melnyk at the time, to help it become a very strong company. And we did a lot of products at Biovail, a lot of research was done. At the time, I was the Chief Scientific Officer and the Vice-President for Research and Development of New Technologies.
Around ’98, I left Biovail, and then my wife, who had earlier on set up Intellipharmaceutics in 1996 as a consulting company, and then we decided to vertically integrate the company, make it an R&D company and a manufacturing company. So it’s since 1998; it’s been a long time, but this is truly one of the true Canadian companies, it’s Canadian based, and although we are now public on NASDAQ and TSX, we can still lay claim to the fact that this is truly a Canadian company.
James West: Interesting, that’s a great story. Was Biovail the precursor to Valeant?
Dr. Isa Odidi: Yes, it is the precursor to Valeant. A successful company, Biovail. Very proud of the work we did there.
James West: Right. Okay, so what other products do you have in the pipeline at Intellipharmaceutics that might add to the future success?
Dr. Isa Odidi: Okay, we have several, and they have not been made public, so therefore I’m not going to speak about them. But the one that was made public is pregabalin. Pregabalin is used for fibromyalgia and neuropathy. Currently pregabalin is taken as a twice or three times a day product. We’ve come up with a technology platform that will allow you to take this product once a day. Not only that, it also gives better coverage with regards to the exposure of patients to the drug in the sense that, given the dosing regimen that we are applying for this product, if it becomes approved, that’s after doing our first clinical trials, is a product we are trying to dose just at night before going to bed. And we think this helps cover the problem that fibromyalgia patients are talking about, the drug they’re currently taking perhaps is not giving them enough coverage and exposure.
So I think that’s the next big thing, and here we’re targeting a market that is currently over $3 billion.
And then there are several combination products that are coming for opiates, these are based on our PODRAS technology, the abuse deterrent technology and the overdose technology. And then we are looking at several other once-a-day products with regards to hydromorphone,oxymorphone and hydrocodone. And like I said earlier, there are several more we haven’t made public, and therefore I won’t be able to talk about them.
James West: Lineup, I’m impressed. I’ve not heard of your company, but now that I have, we’re going to follow it with interest. I’d like to thank you for your time today.
Dr. Isa Odidi: Thank you very much for giving me the opportunity to speak to you, and your big audience.
James West: You bet. Thank you. Bye-bye.
Dr. Isa Odidi: Bye.
FTNW hope this continues to go up.
Although it will be bittersweet for me.
I had a GTC order in for a long time that was 1.05 to keep my shares from getting borrowed for shorting...unfortunately I forgot about it and as the PPS kept rising, I didn't change it.
So...Good news is that I just made about $67K...bad news is that I think I could have made a lot more. I was in AVG .35
So, i'll be standing on the side lines watching for a little bit hoping for another dip to buy back in.
Good Luck everyone!
The small blocks of accumulation are going on again today...signs of good things?
One can only hope!
It will be nice to see this finally over $5 PPS, then we can watch the major hedge funds jump in and take the float away!
Good luck everyone!
Long IPCI
Time to announce the deal...
October 7, 2016: Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®
October 11, 2016: Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt
February 24, 2017: Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
March ??, 2017: Intellipharmaceutics Announces ???????
You have got to believe there is a deal brewing...it only took four days for the Mallinckrodt deal to be brokered, and today makes two weeks since the Glacophage approval.
Show me the money!...(Jerry McGuire)!
Long IPCI
Whomever the partner is, I hope they make announcements soon.
Partnership with Glucophage, possible partnership with Keppra, and an impending partnership with Rexista.
The steady walk down of the PPS is disheartening when you know at any day a PR could be released to sustain the PPS. Any number of PRs would stop the steady walk down, and possibly create a huge feeding frenzy of buyers trying to get in. Just the announcement of Glucophage caused a 5 Million share day, what will the partnership cause? What will the Rexista partnership cause?
Time will tell...I just hope the time is sooner rather than later!
Good Luck everyone!
Long IPCI!
$$ GBLX $$ Medical Cannabis $$ GBLX $$
SEATTLE, WA--(Marketwired - Mar 7, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the complex nature of the cannabis plant and the entourage effect of the plant's cannabinoids, terpenes, and other phytochemicals. GB Sciences Inc.'s ( OTCQB : GBLX ) holistic approach to cannabis drug development is a reflection and an embrace of this complexity.
THC-only pharmaceuticals, like Marinol (dronabinol) and Cesamet (nabilone), have experienced limited efficacy. In fact, less than 2% of patients in a 2011 survey preferred THC-only pharmaceuticals over inhaled or infused delivery methods. CBD-only therapies have proven much more beneficial -- particularly with conditions like epilepsy -- but emerging evidence has shown that combinations of these cannabinoids could be even more beneficial.
Dr. Than Russo, M.D., a neurologist who has become an expert in cannabinoids, notes many of these synergies in his study "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects," which details many cannabinoid interactions.
There are also over 100 other cannabinoids in the cannabis plant that work together to reach therapeutic goals. For example, CBC is the third most common cannabinoid in the cannabis plant and works with THC to fight inflammation. THCv is another cannabinoid that has been shown to mitigate some of the negative psychoactive impacts of THC. These kinds of combinations could produce safer and more effective therapies targeting many conditions.
GB Sciences has embraced the complexity of both the cannabis plant and endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between hundreds of cannabinoids, terpenes, and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using a high-throughput screening system that incorporates cellular and animal models of disease, as well as in silico experiments run with sophisticated algorithms.
Recently, the company filed a series of patents covering cannabinoid-containing complex mixtures, addressing areas like neuronal protection (Parkinson's, Alzheimer's, Huntington's, etc.) and inflammation (arthritis, IBS, Crohn's, asthma, etc.). The company also licensed an existing patent from Makai Biotechnology covering therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies of the cardiovascular system.
With these patents in place, GB Sciences recently engaged a California-based contract research organization that will help complete pre-clinical trials on animals, file an Investigational New Drug application to begin human testing, and conduct its first human clinical trials. The company is taking a very clinical approach to the market to ensure the highest levels of standardization for both safety and efficacy reasons. Its manufacturing facility features standardized cultivation and extraction techniques designed to produce products with refined clinical properties, and it is applying for ISO certification for the facility. These levels of standardization are necessary for regulatory approvals as it moves into clinical trials.
Please follow the link to read the full article: http://www.cannabisfn.com/cannabinoids-work-best-together/
$$ GBLX $$ Medical Cannabis $$ GBLX $$
SEATTLE, WA--(Marketwired - Mar 7, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the complex nature of the cannabis plant and the entourage effect of the plant's cannabinoids, terpenes, and other phytochemicals. GB Sciences Inc.'s ( OTCQB : GBLX ) holistic approach to cannabis drug development is a reflection and an embrace of this complexity.
THC-only pharmaceuticals, like Marinol (dronabinol) and Cesamet (nabilone), have experienced limited efficacy. In fact, less than 2% of patients in a 2011 survey preferred THC-only pharmaceuticals over inhaled or infused delivery methods. CBD-only therapies have proven much more beneficial -- particularly with conditions like epilepsy -- but emerging evidence has shown that combinations of these cannabinoids could be even more beneficial.
Dr. Than Russo, M.D., a neurologist who has become an expert in cannabinoids, notes many of these synergies in his study "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects," which details many cannabinoid interactions.
There are also over 100 other cannabinoids in the cannabis plant that work together to reach therapeutic goals. For example, CBC is the third most common cannabinoid in the cannabis plant and works with THC to fight inflammation. THCv is another cannabinoid that has been shown to mitigate some of the negative psychoactive impacts of THC. These kinds of combinations could produce safer and more effective therapies targeting many conditions.
GB Sciences has embraced the complexity of both the cannabis plant and endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between hundreds of cannabinoids, terpenes, and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using a high-throughput screening system that incorporates cellular and animal models of disease, as well as in silico experiments run with sophisticated algorithms.
Recently, the company filed a series of patents covering cannabinoid-containing complex mixtures, addressing areas like neuronal protection (Parkinson's, Alzheimer's, Huntington's, etc.) and inflammation (arthritis, IBS, Crohn's, asthma, etc.). The company also licensed an existing patent from Makai Biotechnology covering therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies of the cardiovascular system.
With these patents in place, GB Sciences recently engaged a California-based contract research organization that will help complete pre-clinical trials on animals, file an Investigational New Drug application to begin human testing, and conduct its first human clinical trials. The company is taking a very clinical approach to the market to ensure the highest levels of standardization for both safety and efficacy reasons. Its manufacturing facility features standardized cultivation and extraction techniques designed to produce products with refined clinical properties, and it is applying for ISO certification for the facility. These levels of standardization are necessary for regulatory approvals as it moves into clinical trials.
Please follow the link to read the full article: http://www.cannabisfn.com/cannabinoids-work-best-together/
$$$ GBLX $$$ Best Medical MJ stock going!
GB Sciences Seeks Patent for Cannabis-based Treatment for Bowel Diseases
https://ibdnewstoday.com/2017/02/07/gb-sciences-seeks-patent-for-marijuana-based-therapy-for-inflammatory-bowel-diseases/
Growblox Sciences Announces Patent Application for Treatments of Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Dementia
http://www.prnewswire.com/news-releases/growblox-sciences-announces-patent-application-for-treatments-of-parkinsons-disease-alzheimers-disease-huntingtons-disease-and-dementia-300343440.html
GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease.
LAS VEGAS, Dec. 13, 2016 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that its wholly-owned subsidiary, Growblox Life Sciences, LLC has licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.
"GB Sciences is a drug discovery company focused on the development of novel therapeutics based on cannabinoids, terpenoids, and flavonoids from cannabis plants, and is naturally positioned to develop this intellectual property into new medicines. Licensing this TRPV1 patent underscores our drug discovery commitment to targeting the non-classical cannabinoid receptors, beyond the usual CB1 and CB2 receptors," says Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "Our vision of novel, patentable cannabis-based formulations in the treatment of major diseases is now married with a proven drug target for modulation of adverse outcomes in cardiovascular disease. Cannabinoids in native plant extracts exerted a more significant effect on TRPV1 receptors than purified cannabinoids in published research reports, and GB Sciences' cannabis-plant-based approach may provide additional clinical benefits to patients due to the 'entourage effect'. In addition, the side effect profiles of cannabis-based therapies have generally been well tolerated."
"Cardiovascular disease is the leading global cause of death, accounting for more than 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. In the US, this equates to one in three deaths, about one every 40 seconds, and costs the US approximately $316.6 billion a year. Patients urgently need new drug regimens that can ameliorate or reverse the stages of cardiac hypertrophy and heart failure," says Dr. Alexander Stokes, Founder and President of Makai Biotechnology. "TRPV1 is clearly a major mechanistic player in the progression to heart failure, and there is great potential for proprietary mixtures within the GB Life Sciences portfolio to regulate the TRPV1 cannabinoid receptor."
GB Sciences CEO John Poss remarked: "This license is an important step in our Company's march to successful drug discovery. We are very proud of Dr. Small-Howard and her team, and we expect results from this effort that will enable the company to do well by doing good for literally millions of cardiac patients around the world."
Chart seems to be stabilizing...maybe $2.40 is the new base?
Can't wait for the partnership deal to get PR'd. Hope to catch a lot of shorts off guard!
Best of luck everyone!
Long IPCI